Approvals (Drugs@FDA)

ELIQUIS

BRISTOL MYERS SQUIBB · APIXABAN

NDA202155Drug (NDA)Prescription
Open FDA's page for this record
Application number
NDA202155
Sponsor name
BRISTOL MYERS SQUIBB
Submissions
  1. Submission type
    SUPPL
    Submission number
    20
    Submission status
    AP
    Submission status date
    20180628
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      54762
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202155s020lbl.pdf
      Date
      20180705
      Type
      Label
    2. ID
      54836
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/202155Orig1s020ltr.pdf
      Date
      20180706
      Type
      Letter
  2. Submission type
    SUPPL
    Submission number
    12
    Submission status
    AP
    Submission status date
    20160720
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      40134
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202155s012lbl.pdf
      Date
      20160721
      Type
      Label
    2. ID
      9979
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202155Orig1s012ltr.pdf
      Date
      20160722
      Type
      Letter
  3. Submission type
    SUPPL
    Submission number
    10
    Submission status
    AP
    Submission status date
    20150616
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      19076
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202155s010lbl.pdf
      Date
      20150619
      Type
      Label
    2. ID
      32197
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/202155Orig1s010ltr.pdf
      Date
      20150618
      Type
      Letter
  4. Submission type
    SUPPL
    Submission number
    39
    Submission status
    AP
    Submission status date
    20250417
    Review priority
    PRIORITY
    Submission class code
    EFFICACY
    Submission class code description
    Efficacy
    Application docs
    1. ID
      82023
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/202155Orig1s039, s040ltr.pdf
      Date
      20250428
      Type
      Letter
    2. ID
      84394
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202155Orig1s039,s040lbl.pdf
      Date
      20251212
      Type
      Label
  5. Submission type
    ORIG
    Submission number
    1
    Submission status
    AP
    Submission status date
    20121228
    Review priority
    PRIORITY
    Submission class code
    TYPE 1
    Submission class code description
    Type 1 - New Molecular Entity
    Application docs
    1. ID
      9975
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202155Orig1s000ltr.pdf
      Date
      20130102
      Type
      Letter
    2. ID
      19071
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
      Date
      20121231
      Type
      Label
    3. ID
      22875
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.html
      Date
      20130213
      Type
      Review
  6. Submission type
    SUPPL
    Submission number
    8
    Submission status
    AP
    Submission status date
    20150501
    Review priority
    PRIORITY
    Submission class code
    MANUF (CMC)
    Submission class code description
    Manufacturing (CMC)
  7. Submission type
    SUPPL
    Submission number
    6
    Submission status
    AP
    Submission status date
    20140821
    Review priority
    STANDARD
    Submission class code
    EFFICACY
    Submission class code description
    Efficacy
    Application docs
    1. ID
      9976
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202155Orig1s006ltr.pdf
      Date
      20140910
      Type
      Letter
    2. ID
      19075
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s006lbl.pdf
      Date
      20140909
      Type
      Label
  8. Submission type
    SUPPL
    Submission number
    17
    Submission status
    AP
    Submission status date
    20171129
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      50532
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202155s017lbl.pdf
      Date
      20171130
      Type
      Label
    2. ID
      50563
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202155Orig1s017ltr.pdf
      Date
      20171201
      Type
      Letter
  9. Submission type
    SUPPL
    Submission number
    4
    Submission status
    AP
    Submission status date
    20131031
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      19074
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202155Orig1s004lbl.pdf
      Date
      20131119
      Type
      Label
    2. ID
      32196
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/202155Orig1s004ltr.pdf
      Date
      20131106
      Type
      Letter
  10. Submission type
    SUPPL
    Submission number
    2
    Submission status
    AP
    Submission status date
    20140130
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      19072
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202155s002lbl.pdf
      Date
      20140131
      Type
      Label
    2. ID
      22876
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202155Orig1s002TOC.html
      Date
      20140321
      Type
      Review
    3. ID
      32194
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202155Orig1s002ltr.pdf
      Date
      20140204
      Type
      Letter
  11. Submission type
    SUPPL
    Submission number
    21
    Submission status
    AP
    Submission status date
    20190603
    Review priority
    STANDARD
    Submission class code
    LABELING
    Submission class code description
    Labeling
    Application docs
    1. ID
      58969
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202155s021lbl.pdf
      Date
      20190604
      Type
      Label
    2. ID
      58977
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/202155Orig1s021ltr.pdf
      Date
      20190605
      Type
      Letter
  12. Submission type
    SUPPL
    Submission number
    13
    Submission status
    AP
    Submission status date
    20160503
    Review priority
    PRIORITY
    Submission class code
    MANUF (CMC)
    Submission class code description
    Manufacturing (CMC)
    Application docs
    1. ID
      44989
      Url
      http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/202155Orig1s013.pdf
      Date
      20160503
      Type
      Review
  13. +13 more not shown
Products
  1. Product number
    003
    Reference drug
    Yes
    Brand name
    ELIQUIS
    Reference standard
    Yes
    Dosage form
    TABLET, FOR SUSPENSION
    Route
    ORAL
    Marketing status
    Prescription
    Active ingredients
    1. Name
      APIXABAN
      Strength
      0.5MG
  2. Product number
    001
    Reference drug
    Yes
    Brand name
    ELIQUIS
    Reference standard
    No
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      APIXABAN
      Strength
      2.5MG
  3. Product number
    002
    Reference drug
    Yes
    Brand name
    ELIQUIS
    Reference standard
    Yes
    Dosage form
    TABLET
    Route
    ORAL
    Marketing status
    Prescription
    Te code
    AB
    Active ingredients
    1. Name
      APIXABAN
      Strength
      5MG
Harmonized identifiers (openFDA)
Application number
NDA202155
Brand name
ELIQUIS, ELIQUIS 30-DAY STARTER PACK
Generic name
APIXABAN
Manufacturer name
E.R. Squibb & Sons, L.L.C.
Product NDC
0003-0893, 0003-0894, 0003-3764, 0003-1028, 0003-0898
Product type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Substance name
APIXABAN
RxCUI
1364435, 1364441, 1364445, 1364447, 1992427, 1992428, 2749579, 2749583, 2749685, 2749689, 2749694, 2749695, 2749697, 2749698, 2749699, 2749700
SPL ID
188961fc-00f8-4848-a611-c3c85764baf8
SPL set ID
e9481622-7cc6-418a-acb6-c5450daae9b0
Package NDC
0003-0893-21, 0003-0893-31, 0003-0893-91, 0003-0894-21, 0003-0894-70, 0003-0894-31, 0003-0894-91, 0003-3764-74, 0003-1028-28, 0003-1028-84, 0003-1028-12, 0003-0898-28
Nui
N0000175637, N0000175635
Pharm class epc
Factor Xa Inhibitor [EPC]
Pharm class moa
Factor Xa Inhibitors [MoA]
UNII
3Z9Y7UWC1J
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.